Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS – Get Rating) – Investment analysts at SVB Leerink cut their FY2023 earnings estimates for shares of Marinus Pharmaceuticals in a report issued on Monday, January 23rd. SVB Leerink analyst M. Goodman now expects that the biopharmaceutical company will post earnings per share of ($3.25) for the year, down from their prior forecast of ($2.90). SVB Leerink has a "Outperform" rating and a $23.00 price objective on the stock. The consensus estimate for Marinus Pharmaceuticals' current full-year earnings is ($2.88) per share. SVB Leerink also issued estimates for Marinus Pharmaceuticals' FY2024 earnings at ($2.50) EPS, FY2025 earnings at ($1.50) EPS and FY2026 earnings at $1.10 EPS.
Get
Marinus Pharmaceuticals alerts:
Marinus Pharmaceuticals (NASDAQ:MRNS – Get Rating) last released its earnings results on Monday, November 7th. The biopharmaceutical company reported ($0.35) earnings per share for the quarter, missing analysts' consensus estimates of $0.25 by ($0.60). Marinus Pharmaceuticals had a negative return on equity of 244.60% and a negative net margin of 77.96%. The business had revenue of $2.34 million during the quarter, compared to analysts' expectations of $28.56 million.
A number of other research analysts have also weighed in on MRNS. StockNews.com raised shares of Marinus Pharmaceuticals from a "sell" rating to a "hold" rating in a research note on Monday, November 14th. HC Wainwright reaffirmed a "buy" rating and set a $27.00 price target on shares of Marinus Pharmaceuticals in a research report on Friday, January 6th. Robert W. Baird reduced their price target on shares of Marinus Pharmaceuticals from $32.00 to $24.00 and set an "outperform" rating on the stock in a research report on Wednesday, November 9th. Finally, Royal Bank of Canada began coverage on shares of Marinus Pharmaceuticals in a research report on Friday, January 20th. They set an "outperform" rating and a $23.00 price target on the stock. One investment analyst has rated the stock with a hold rating and seven have given a buy rating to the company's stock. Based on data from MarketBeat.com, Marinus Pharmaceuticals currently has an average rating of "Moderate Buy" and a consensus price target of $28.13.
Marinus Pharmaceuticals Trading Up 4.6 %
MRNS opened at $5.96 on Wednesday. The company has a debt-to-equity ratio of 0.91, a current ratio of 8.41 and a quick ratio of 8.40. The company's 50 day simple moving average is $4.47 and its two-hundred day simple moving average is $5.47. Marinus Pharmaceuticals has a 1-year low of $3.46 and a 1-year high of $12.37. The firm has a market capitalization of $221.69 million, a price-to-earnings ratio of -12.96 and a beta of 1.10.
Institutional Trading of Marinus Pharmaceuticals
Institutional investors have recently added to or reduced their stakes in the stock. Amalgamated Bank acquired a new stake in Marinus Pharmaceuticals in the 1st quarter valued at approximately $56,000. Renaissance Technologies LLC acquired a new stake in Marinus Pharmaceuticals in the 1st quarter valued at approximately $317,000. Virtu Financial LLC acquired a new stake in Marinus Pharmaceuticals in the 1st quarter valued at approximately $221,000. MetLife Investment Management LLC increased its holdings in Marinus Pharmaceuticals by 63.8% in the 1st quarter. MetLife Investment Management LLC now owns 20,363 shares of the biopharmaceutical company's stock valued at $190,000 after purchasing an additional 7,928 shares during the last quarter. Finally, Price T Rowe Associates Inc. MD grew its stake in shares of Marinus Pharmaceuticals by 39.5% in the second quarter. Price T Rowe Associates Inc. MD now owns 15,600 shares of the biopharmaceutical company's stock worth $76,000 after acquiring an additional 4,417 shares in the last quarter. Institutional investors and hedge funds own 86.88% of the company's stock.
Marinus Pharmaceuticals Company Profile
(Get Rating)
Marinus Pharmaceuticals, Inc, a pharmaceutical company, focuses on development and commercialization of products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY, an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings.
Read More
- Get a free copy of the StockNews.com research report on Marinus Pharmaceuticals (MRNS)
- AMD Is Still One Of The Best Semiconductor Stocks Out There
- Two Dividend Kings: Johnson & Johnson or Abbott Laboratories?
- Is The Bottom In For Cyber-Security Stocks?
- Union Pacific, Norfolk Southern Pull into Buying Zone
- Pliant Therapeutics Gaps 34% Higher: More Upside To Come?
Receive News & Ratings for Marinus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Marinus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
